Delving into the Latest Updates on EGF1-48 with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Target-

Mechanism

Myelin proteins stimulants

Therapeutic Areas

Nervous System Diseases

Active Indication

Neurodegenerative Diseases

Inactive Indication-

Originator Organization

Cresence AS

Active Organization

Cresence AS

Inactive Organization-

Drug Highest PhaseClinical

First Approval Date-

Regulation-

BACKGROUND AND AIMSNeonatal necrotizing enterocolitis (NEC) is a common and serious acquired gastrointestinal tract condition. This clinical study assessed the potential clinical efficacy and microscopic effects of recombinant human epidermal growth factor 1-48 (EGF(1-48)) in neonates with NEC.METHODSThis prospective, double-blind, randomized controlled study included 8 neonates with NEC. The study compared the effects of a 6-day continuous intravenous infusion of EGF(1-48) at 100 ng kg(-1) h(-1) against placebo. Clinical outcomes and morphological evaluation of serial rectal mucosal biopsies were assessed at baseline and 4, 7, and 14 days after starting EGF infusions.RESULTSThere was no difference between the clinical safety outcomes recorded for EGF(1-48) or placebo patients. Quantitative morphologic differences in the rectal mucosa biopsies were noted with EGF(1-48) treatment compared with baseline or placebo and included a statistically significant increase in the number of mitoses per mucosal crypt on study day 4, significantly increased thickness of rectal mucosa from baseline on study days 4 and 7, and increased crypt surface area of rectal mucosa in parallel with increased mucosa thickness on day 14.CONCLUSIONThis study of EGF(1-48) in neonates with severe NEC showed that growth factor treatment was well tolerated and produced positive and measurable remodeling trophic effects on the gastrointestinal mucosa.

100 Deals associated with EGF1-48

Login to view more data